Skip to main content
. 2022 Nov;11(11):2289–2305. doi: 10.21037/tlcr-22-732

Figure 3.

Figure 3

Pie chart showing the distribution irAEs in the rechallenged group (A). Venn diagram of irAEs distribution in patients without CIP recurrence (B) and with CIP recurrence (C). irAEs, immune-related adverse events; CIP, checkpoint inhibitor-related pneumonitis.